Agreement with BioView to develop a CTC-based HER2 assay First phase expected to generate c. £1.2 million revenue GUILDFORD, UK / ACCESSWIRE / April 19, 2023 / ANGLE plc (AIM:AGL), (OTCQX:ANPCY), a ...

There’s a reason cigarette boxes contain a warning, telling smokers that they could die from lung cancer if they habitually puff. In the US, lung cancer kills more people annually than does any other ...

ANGLE (OTCQX:ANPCY) signs an agreement with BioView to develop a liquid biopsy circulating tumor cell (or CTC) HER2 assay for breast cancer. It will be utilising ANGLE's FDA cleared Parsortix PC1 ...

Lung cancer spreads quickly, which helps it claim more lives each year than any other cancer worldwide and makes early detection key. Now, two companies have teamed up to bring a diagnostic test to ...

BioView and ScreenCell inked a commercial collaboration that will apply BioView’s Automated Cell Imaging Systems to image circulating tumor cells (CTCs) isolated using ScreenCell’s CytoKit® platform.

This development is based on a press release statement and represents an ongoing effort to enhance cancer diagnostics through less invasive methods, with the potential to impact treatment strategies ...

ANGLE AND BIOVIEW TO PRESENT COMBINED SOLUTION FOR CIRCULATING TUMOR CELL DETECTION AND ANALYSIS AT MOLECULAR MED TRI-CON 2020 IN SAN FRANCISCO, 4 MARCH 2020 GUILDFORD, SURREY / ACCESSWIRE / February ...

Vortex Biosciences and BioView Announce Collaboration for Clinical Biomarker Identification on Circulating Tumor Cells London, UK - 13 March 2018 - NetScientific plc ("NetScientific", AIM:NSCI), the ...

ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce it has signed an agreement with BioView Ltd. ("BioView") (BIOV.TA) to develop a liquid biopsy ...

BioView President and CEO, Dr. Alan Schwebel, commented: "We are excited for this development partnership opportunity with ANGLE, where we plan to leverage the strengths of both our technologies to ...